Concerning these findings, we propose that peripheral blood mRNA levels of different genes (such PTGDR2) should be explored as new minimally invasive biomarkers that might assist in the molecular phenotyping of asthma and selecting patients for treatment with specific antagonists. This evidence concerns the gene PTGDR2 and asthma.